EPIX
Price:
$1.83
Market Cap:
$81.20M
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.[Read more]
Industry
Biotechnology
IPO Date
2015-03-13
Stock Exchange
NASDAQ
Ticker
EPIX
According to ESSA Pharma Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 36.95. This represents a change of -3.50% compared to the average of 38.29 of the last 4 quarters.
The mean historical Current Ratio of ESSA Pharma Inc. over the last ten years is 25.61. The current 36.95 Current Ratio has changed 14.32% with respect to the historical average. Over the past ten years (40 quarters), EPIX's Current Ratio was at its highest in in the March 2023 quarter at 73.86. The Current Ratio was at its lowest in in the December 2017 quarter at 0.62.
Average
25.61
Median
7.31
Minimum
1.48
Maximum
73.38
Discovering the peaks and valleys of ESSA Pharma Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 581.15%
Maximum Annual Current Ratio = 73.38
Minimum Annual Increase = -48.19%
Minimum Annual Current Ratio = 1.48
Year | Current Ratio | Change |
---|---|---|
2023 | 42.57 | -41.98% |
2022 | 73.38 | 45.93% |
2021 | 50.28 | -24.86% |
2020 | 66.92 | 581.15% |
2019 | 9.82 | 105.12% |
2018 | 4.79 | 222.65% |
2017 | 1.48 | -48.19% |
2016 | 2.87 | 24.65% |
2015 | 2.30 | 33.82% |
2014 | 1.72 | 28.03% |
The current Current Ratio of ESSA Pharma Inc. (EPIX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
55.41
5-year avg
48.60
10-year avg
25.61
ESSA Pharma Inc.’s Current Ratio is greater than Altamira Therapeutics Ltd. (1.38), greater than Summit Therapeutics Inc. (8.31), greater than Avenue Therapeutics, Inc. (2.67), greater than Spero Therapeutics, Inc. (2.68), greater than Aeglea BioTherapeutics, Inc. (4.59),
Company | Current Ratio | Market cap |
---|---|---|
1.38 | $1.60M | |
8.31 | $14.00B | |
2.67 | $3.84M | |
2.68 | $63.24M | |
4.59 | $48.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ESSA Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ESSA Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is ESSA Pharma Inc.'s Current Ratio?
How is the Current Ratio calculated for ESSA Pharma Inc. (EPIX)?
What is the highest Current Ratio for ESSA Pharma Inc. (EPIX)?
What is the 3-year average Current Ratio for ESSA Pharma Inc. (EPIX)?
What is the 5-year average Current Ratio for ESSA Pharma Inc. (EPIX)?
How does the current Current Ratio for ESSA Pharma Inc. (EPIX) compare to its historical average?